Mylan has announced the U.S. launch of Exemestane Tablets, 25 mg, a generic version of the reference listed drug, Pfizer’s Aromasin® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated in the treatment of certain types of breast cancer in women after menopause.
Mylan is the largest supplier of cancer medicines by volume in the U.S., and the launch of Exemestane Tablets, 25 mg, adds to the company’s robust oncology franchise. Exemestane Tablets, 25 mg, had U.S. sales of approximately $100 million for the 12 months ending Jan. 31, 2017, according to IMS Health.
Currently, Mylan has 240 ANDAs pending FDA approval representing approximately $100.8 billion in annual brand sales, according to IMS Health. Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $39 billion in annual brand sales, for the 12 months ending Dec. 31, 2016, according to IMS Health.
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what’s right, not what’s easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 7,500 marketed products around the world, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS in the developing world depend. We market our products in more than 165 countries and territories. We are one of the world’s largest producers of active pharmaceutical ingredients. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time.